AACR 2017: Adding the IDO-Pathway Inhibitor Indoximod to Pembrolizumab Improved Response Rate in Melanoma
Adding the investigational immunotherapy indoximod to the immunotherapy pembrolizumab (Keytruda) increased the proportion of patients with advanced melanoma who responded to treatment compared with previously reported response rates for pembrolizumab monotherapy, according to interim results from a phase I/II clinical trial presented by Zakharia et al at the 2017 American Association for Cancer Research (AACR) Annual Meeting (Abstract CT117).
“In the phase III KEYNOTE-006 clinical trial that led the U.S. Food and Drug Administration (FDA) to approve the immune checkpoint inhibitor pembrolizumab as an initial treatment for patients with advanced melanoma, the overall response rate was 33%, meaning 33% of patients had partial or complete shrinkage of their tumors,” said Yousef N. Zakharia, MD, Assistant Professor in the Department of Internal Medicine at the University of Iowa, Iowa City. “We set out to investigate whether we could improve upon this response rate by adding an inhibitor of the IDO pathway to pembrolizumab treatment.”
He continued: “We are excited to share interim results from the phase II portion of this clinical trial, because the data show that 52% of patients treated with a combination of pembrolizumab and the IDO-pathway inhibitor indoximod had a partial or complete response without significant added toxicities.” Dr. Zakharia is also co-leader of the early-phase clinical trials program at the Holden Comprehensive Cancer Center at the University of Iowa.
“It is noteworthy that this trial did not exclude ocular melanoma, which has been shown to be more aggressive and less responsive to available systemic treatment,” added Dr. Zakharia. “Most comparable trials do not allow patients with ocular melanoma. When the results are considered without the ocular melanoma patients (9 of 60), the response rate in cutaneous and nonocular melanoma is actually 59%. These robust data are very promising, but we need to confirm the clinical benefit in a larger, randomized trial.”
Dr. Zakharia explained that the normal function of the IDO pathway is to keep the immune system in check, preventing it from responding inappropriately “However, some tumors hijack the pathway, using it to prevent the immune system from attacking and destroying the tumors, suggesting that it could be a good target for cancer immunotherapy,” he said.
Phase Ib Trial
Results previously reported at the 2016 ASCO Annual Meeting (Abstract 3075), from the phase Ib portion of the clinical trial, showed that the combination of indoximod and the FDA-approved immune checkpoint inhibitor ipilimumab (Yervoy) was well tolerated and caused no increase in toxicity compared with the immune checkpoint inhibitor used alone.
Phase II Trial
In the phase II portion of the clinical trial, patients received indoximod and FDA-approved immune checkpoint inhibitor therapy of the treating physician’s choice, either ipilimumab, pembrolizumab, or nivolumab (Opdivo). Most patients received indoximod (1,200 mg orally twice every day) with pembrolizumab, which was infused at the standard dose of 3 mg/kg every 21 days.
The new data being reported were obtained with a January 2017 cutoff. After a median follow up of 10.5 months, 6 of 60 patients had a complete response and 25 had a partial response, giving an overall response rate of 52%. The most common adverse events were fatigue, diarrhea, and nausea.
“The trial is still accruing patients, and we are continuing to monitor all of the patients enrolled so far,” said Dr. Zakharia. “This interim analysis represents the largest reported number of melanoma patients treated with the combination of an IDO-pathway inhibitor and standard checkpoint inhibitors to date.”
According to Dr. Zakharia, the main limitation of the study is that the clinical trial had no control arm, which means that a large-scale, placebo-controlled randomized clinical trial is needed to confirm the current results.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
